Background {#Sec1}
==========

Autoimmune arthropathies are treated with biologics that allowed remarkable advancement in the control of disease alteration \[[@CR1]\]. However, some patients do not respond to the first biologic, or even to the others successively given with or without methotrexate and studies to identify predictors of response to biologic therapy are still limited \[[@CR2]\]. The classical predictors such as the presence of auto-antibodies \[the rheumatoid factor (RF) and the anti-cyclic citrullinated peptide (anti-CCP)\], genotypes encoding the shared epitope *HLA*-*DRB1* gene, smoking and/or periodontitis are largely insufficient to foresee the patient response to a biologic \[[@CR3]\]. Genetic predictors represent an ongoing field of research and bear the potential to contribute to the development of a precision medicine approach in the management of autoimmune arthropathies \[[@CR4], [@CR5]\]. Nonetheless, the identification of genetic markers of disease outcome and response to treatment is still at its infancy and has been somewhat disappointing so far \[[@CR6]\].

The most fruitful findings to treat autoimmune arthropathies remain the characterization of immune mediators involved in the disease. This is greatly supported by the numerous biologics readily available to treat most of the autoimmune diseases, including biotherapies targeting specific immune cells, such as the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4, also known as CD152) or the B-lymphocyte antigen CD20, or secreted mediators like the pro-inflammatory cytokines tumor necrosis factor (TNF), interleukin (IL)-1, IL-6, IL-12/IL-23 and IL-17 \[[@CR7]\]. Although a range of treatment options can be addressed with biologics, none of them are universally effective and the best treatment selection is still based on a trial-and-error approach, where the most suitable one is determined when a drug reduces disease activity or remission is identified \[[@CR8]\]. Considering the severity of these life-threatening diseases and the high cost of biologics, the best treatment option should target, from the start, the patients' own pattern of cytokines \[[@CR9]\].

Here, we report a clinical case demonstrating the usefulness of examining the leukocytes' secretome of patients. We set up and standardized a protocol that investigates the immune responses of the patients to establish the secretome of their blood mononuclear leukocytes. The results were used to personalize the biotherapy of a patient suffering from an autoimmune arthropathy, providing insights on how to tailor the best treatment option and therefore avoid definitive disability and loss of quality of life.

Case presentation {#Sec2}
=================

A 24-year-old woman was examined for the first time 3 months after the onset of symmetrical polyarthritis with major synovitis of 2nd, 3rd, 4th metacarpophalangeal joints of both hands, wrists, elbows, knees, ankles, forefeet, without any spinal signs. The disease activity score of 28 joints (DAS28) and DAS28 using the C-reactive protein (DAS28-CRP) were 8.09 and 7.75, respectively. Increased ferritin and thrombocytosis in the absence of detectable levels of RF, anti-CCP and antinuclear antibody (ANA) were also noticeable. Her liver function tests and lipid panel were normal and no bone erosion was visible by X-rays. She was diagnosed with active early rheumatoid arthritis (RA) (Table [1](#Tab1){ref-type="table"}).Table 1Patient information and diagnostics summaryTime since onset of disease3 months1 year2 years5 years10 years11 yearsClinical parameters DAS288.098.377.946.877.613.76 DAS28-CRP7.757.987.556.637.444.34 Bone erosions at X-raysNoneNoneYesYesYesYesBiological parameters ESR (mm, first hour; Nl \< 20)6368378245 CRP (mg/L; Nl \< 10)5685251187 Ferritin (μg/mL; Nl \< 200)347314202141165Not evaluated Platelet count (Nl \< 400 billion/L)469390348225247263 RFUndetectableUndetectableUndetectableUndetectableUndetectableUndetectable Anti-CCPUndetectableUndetectableUndetectableUndetectableUndetectableUndetectable ANAUndetectableUndetectableUndetectableUndetectableUndetectableUndetectable Synovial fluid analysis8.93 billion WBC/L21.15 billion WBC/L120.8 billion WBC/L99% neutrophils99% neutrophils83% neutrophilsDiagnosisActive early RAActive early RAPossible RA-like PsoARA-like PsoA with bone erosionsRA-like PsoA with bone erosionsRA-like PsoA with bone erosionsTreatment prescribedPrednisoneMethotrexateHydroxychloroquineNaproxenInitial treatment + adalimumab (anti-TNF)Stop adalimumab; Initial treatment + abatacept (IgG1 Fc-CTLA-4)Initial treatment + abatacept (IgG1 Fc-CTLA-4)Stop abatacept; Initial treatment + ustekinumab (anti-IL-12/IL-23)Initial treatment + tocilizumabNotesHLA-B27 absentTreatment at visit: diclofenacSterile synovial fluid was removed by joint aspirationSterile synovial fluid was removed by joint aspirationMother and maternal grandmother have psoriasisAn aunt and her son have inflammatory spondylarthritisAppearance of psoriasis skin lesionsSterile synovial fluid was removed by joint aspirationUstekinimab (anti-IL-12/IL-23) and secukinimab (anti-IL-17) were not authorized at the timeNo improvement after 6 months treatment with ustekinumabStop ustekinumabEnrollement in study to quantify cytokines in plasma and secreted by activated PBMCsTocilizumab (anti-IL-6) begun*ANA* antinuclear antibody, *anti-CCP* anti-cyclic citrullinated peptide, *CRP* C-reactive protein, *DAS28* disease activity score of 28 joints, *ESR* erythrocyte sedimentation rate, *Nl* normal level, *PsoA* psoriatic arthritis, *RA* rheumatoid arthritis, *RF* rheumatoid factor, *WBC* white blood cells

Initial treatments with prednisone, methotrexate, hydroxychloroquine and naproxen were without efficacy. The anti-TNF adalimumab was added to the treatment regimen for 2 years. After only mild improvement, she experienced a progressive flare-up of polyarthritis and a loss of treatment efficacy. Two years after the onset of the disease, wrist and tarsal (right and left) demineralization, as well as bone erosions of ulnar styloids (right and left), appeared. Erythrocyte sedimentation rate (ESR), CRP and ferritin were persistently increased while RF and anti-CCP remained undetectable. The diagnosis was revised as possible RA-like psoriatic arthritis (PsoA), especially as her mother has skin psoriasis. Bone lesions were increased rapidly, in particular at both wrists. Adalimumab was replaced by abatacept (IgG1 Fc-CTLA-4) with a mild effect on arthritis. Five years after disease onset, psoriatic skin lesions appeared, and diagnosis of cutaneous psoriasis was confirmed by a dermatologist. The final diagnosis was aggressive RA-like PsoA with bone erosions, without RF and anti-CCP. Abatacept was replaced by the anti-interleukin (IL)-12/IL-23 ustekinumab with an increase of prednisone dosage. A mild relieve of polysynovitis was noted, which was dependent on prednisone. Reduction of prednisone led to a major flare-up of polysynovitis associated with asthenia, and after 3 months of ustekinumab administration, no objective effect on the patient's symptoms was noted.

The patient was enrolled in a prospective study based on the quantification of cytokines secreted by peripheral blood leukocytes. Blood (50 mL) of the patient as well as of healthy donors was drawn after informed consent was obtained. Plasma was collected following centrifugation (400×*g* for 10 min) of anti-coagulated blood and stored at − 80 °C for further protein quantification. Peripheral blood mononuclear cells (PBMCs) were obtained following centrifugation (600×*g* for 20 min) of the cellular fraction of blood over density gradient medium (Lymphocyte separation medium, density 1.077--1.080 g/mL; Wisent Bioproducts Inc., St-Bruno, Québec, Canada). Density gradient-purified PBMCs were stimulated with well-known immune activators of pattern recognition receptors and cytokine signalling for 24 h at 1 × 10^6^/mL in RPMI 1640 (Wisent Bioproducts Inc., St-Bruno, Québec, Canada) supplemented with 10% fetal bovine serum (VWR Life Science Seradigm, Mississauga, Ontario, Canada) and 1% primocin (InvivoGen, San Diego, California, USA) in the absence (control) or presence of plate-bound mouse anti-human CD3 (1 μg/mL, clone OKT3) + anti-human CD28 (10 μg/mL, clone 9.3), lipopolysaccharides (LPS---100 ng/mL; 45 nM, InvivoGen, San Diego, California, USA) + adenosine triphosphate (ATP---1 mM; added for the last 30 min, Sigma-Aldrich Canada Co., Oakville, Ontario, Canada), L18-muramyl dipeptide (L18-MDP---1 μg/mL; 1.32 μM, InvivoGen, San Diego, California, USA), Poly(deoxyadenylate--thymidylate) \[Poly(dA:dT)---1 μg/mL; 1.57 μM, InvivoGen, San Diego, California, USA\], anisomycin (20 μM, Millipore (Canada) Ltd, Etobicoke, Ontario, Canada) or pro-inflammatory cytokines IL-1β (100 ng/mL; 5.85 nM, PeproTech US, Rocky Hill, New Jersey, USA), TNF (100 ng/mL; 5.85 nM, STEMCELL Technologies Canada Inc., Vancouver, British Columbia, Canada), IL-6 (100 ng/mL; 3.83 nM, PeproTech US, Rocky Hill, New Jersey, USA) and IFN-γ (100 U/mL; 0.30 nM, PeproTech US, Rocky Hill, New Jersey, USA) to respectively activate T cells, the NLRP3, NOD2, AIM2 and pyrin inflammasomes as well as cytokine signalling. Following stimulation, cell supernatants were collected and stored at − 80 °C for further protein quantification. Proteins involved in inflammation (IL-1α, IL-1β, IL-6, IL-9, IL-15, IL-17A, IL-18, IL-21, IL-31, TNF, LT-α, IFN-γ), immunoregulation (IL-1RA, IL-4, IL-7, IL-10, IL-12, IL-13, IL-22, IL-23, IL-27, IFN-α), chemotaxis (CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, CCL11/Eotaxin, CXCL1/GROα, CXCL8/IL-8, CXCL10/IP-10, CXCL12/SDF-1α) and cellular growth (IL-2, IL-5, GM-CSF) were quantified by multiplex analyses in plasma and cell supernatants using Luminex technology according to the manufacturers' instructions (Cytokine & Chemokine 34-Plex Human ProcartaPlex™ Panel 1A, Thermo Fisher Scientific Inc., Burlington, Ontario, Canada).

The results of this study revealed that plasma concentrations of cytokines were similar between the patient and healthy donors (Fig. [1](#Fig1){ref-type="fig"} and data not shown). In comparison to leukocytes from healthy donors, the patient's secretome showed a unique overproduction of IL-6 in response to multiple stimuli, including the inflammasome activators LPS + ATP, MDP and poly(dA:dT), as well as the pro-inflammatory cytokines IL-1β, TNF and IFN-γ, to levels (up to 133,000 pg/mL) at least twice the ones produced by healthy donors' cells (Fig. [2](#Fig2){ref-type="fig"}). This overproduction of IL-6 occurred without substantial increase of pro-inflammatory cytokines such as TNF, IL-12 and IL-23, which correlates with the inefficacy of the anti-TNF adalimumab and the anti-IL-12/IL-23 ustekinumab treatments. No substantial differences were observed for members of the IL-1 cytokine family (IL-1α, IL-1β, IL-18), as well as IFN-γ and IL-17. Increased secretion of the IL-1 receptor antagonist (IL-1RA) was shown upon stimulation with the AIM2 inflammasome activator poly(dA:dT) as well as IFN-γ, suggesting that the patient's leukocytes can synthesize high amounts of IL-1RA to neutralize the production of IL-1. Of note, the stimulation of the patient's T cells using a combination of anti-CD3 and anti-CD28 also led to increased production of IL-6, as well as IL-23, IL-1RA and IL-17, but not to the levels observed for IL-6 (Fig. [2](#Fig2){ref-type="fig"}). Finally, no substantial differences were observed between the patient and the healthy donors regarding the production of IL-2, IL-4, IL-5, IL-7, IL-9, IL-10, IL-13, IL-15, IL-21, IL-22, IL-27, IL-31, LT-α, IFN-α, CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, CCL11/Eotaxin, CXCL1/GROα, CXCL8/IL-8, CXCL10/IP-10 and CXCL12/SDF-1α by unstimulated or stimulated PBMCs (data not shown).Fig. 1Similar levels of cytokines in the plasma of the patient and healthy donors. Concentrations of IL-1α, IL-1β, IL-1RA, IL-18, IL-6, IL-12, IL-23, IL-17, IFN-γ and TNF were determined by multiplex assays in the plasma of healthy donors (black dots) and the patient with aggressive RA-like PsoA (red square). Results are expressed as mean ± standard deviation for the healthy donors (n = 5) Fig. 2Aberrant production of IL-6 by the patient's blood leukocytes. Density gradient-purified peripheral blood mononuclear cells were left unstimulated (unstim) or stimulated for 24 h with anti-CD3 + anti-CD28, lipopolysaccharide (LPS) + adenosine triphosphate (ATP), L18-muramyl dipeptide (L18-MDP), poly(deoxyadenylate--thymidylate) \[poly(dA:dT)\], anisomycin or the pro-inflammatory cytokines IL-1β, TNF, IFN-γ and IL-6 to respectively activate T cells, the NLRP3, NOD2, AIM2 and pyrin inflammasomes as well as cytokine signalling. Concentrations of IL-6, TNF, IL-12, IL-23, IL-1α, IL-1β, IL-18, IL-1RA, IL-17 and IFN-γ were determined by multiplex assays in the cells' supernatants of healthy donors (black dots) and the patient with aggressive RA-like PsoA (red square). Results are expressed as mean ± standard deviation for the healthy donors (n = 5). ND; not determined

Thus, considering the unique major overproduction of IL-6 by the patient's leukocytes, the anti-IL-6 receptor tocilizumab was administered with a rapid improvement of her active PsoA that remained dependent on low prednisone dosage. DAS28 and DAS28-CRP were greatly improved at 3.76 and 4.34, respectively. ESR, CRP and ferritin were progressively normalized. Her quality of life was greatly improved with, in particular, a progressive reduction of asthenia. Have the patient been enrolled in this prospective study sooner, her refractory PsoA would have probably benefited from the personalized treatment without the current associated irreversible destructive arthritis and partial functional handicap, especially at both wrists.

Discussion {#Sec3}
==========

The immunological disease continuum, that includes all autoinflammatory and autoimmune diseases, as proposed by McGonagle & McDermott \[[@CR10]\], allows to better understand the complexity of immune factors that can be associated with the numerous immunological disorders. In this regard, the present case report can possibly be related to polygenic autoinflammatory diseases and mixed pattern diseases, both conceptual classification in which psoriatic arthritis can be found. The investigation of the patient's secretome, as we report here, remains non-exhaustive, with a major focus on the biologics currently available to treat autoimmune arthropathies such as RA and PsoA (Table [2](#Tab2){ref-type="table"}). This focus could easily be extended to other factors depending on new biologics, as well as other stimuli to activate relevant immune signalling as the field progresses further. Nonetheless, the targeted secretome allows deciphering whether a factor could be largely produced over others to be able to adapt more precisely the treatment. This case report exemplifies the personalized treatment option based on the patient's medical history and the determination of the secretome of the patient's blood leukocytes in response to immune activators that revealed a unique overproduction of the IL-6 cytokine. In fact, the overproduction of IL-6 in the present case report of a refractory PsoA was in line with reports of mediators from synovial inflammation of PsoA where anti-IL-6 biologics were effective treatment choices \[[@CR11]--[@CR15]\].Table 2Biotherapies and small molecule inhibitors against secreted mediators or immune cells and their approval for rheumatoid arthritis and psoriatic arthritisTargetAgentStructureMechanism of actionApproval for RAApproval for PsoAFDAHealth CanadaFDAHealth CanadaTNFEtanerceptFusion protein Fc IgG1-TNFR2Decoy receptorNov 1998Dec 2000Jan 2002Mar 2004InfliximabChimeric mAb to TNFAntagonistNov 1999Sep 2001May 2005Jun 2006AdalimumabHumanized mAb to TNFJan 2003Sep 2004Oct 2005Jun 2006GolimumabHuman mAb to TNFApr 2009Apr 2009Oct 2017Apr 2009Certolizumab pegolPegylated Fab' fragment of humanized mAb to TNFMay 2009Sep 2009Sep 2013Jan 2014IL-1AnakinraRecombinant human IL-1 receptorReceptor antagonistNov 2001Jun 2002----CanakinumabHuman mAb to IL-1βAntagonist--------RilonaceptFusion protein Fc IgG1 linked to ligand-binding domains of IL-1R1 and IL-1RAcPCTLA-4AbataceptFusion protein Fc IgG1-CTLA-4Binds CD80 and CD86 on APCs; prevents co-stimulation of T cellsDec 2005Jun 2006Jul 2017Mar 2018CD20RituximabChimeric mAb to CD20Binds CD20 on B cells; triggers cell deathFeb 2006Jun 2006----OcrelizumabHumanized mAb to CD20--------OfatunumabHuman mAb to CD20--------ObinutuzumabHumanized mAb to CD20 with a glycoengineered Fc--------IL-6TocilizumabHumanized mAb to IL-6 receptorReceptor antagonistJan 2010May 2010----SarilumabHuman mAb to IL-6 receptorMay 2017Feb 2017----IL-12, IL-23UstekinumabHuman mAb to IL-12 and IL-23 p40 subunitAntagonist----Sep 2013Jan 2014IL-17SecukinumabHuman mAb to IL-17AAntagonist----Jan 2016Apr 2016IxekizumabHuman mAb to IL-17A----Dec 2017Jun 2018BrodalumabHuman mAb to IL-17 receptor AReceptor antagonist--------Janus kinase 1--3TofacitinibSmall moleculeIntracellular inhibitor; blocks activity of cytokines (IL-2, -4, -6, -7, -9, -10, -12, -15, -21, -23, IFN-α, -β, -γ)Nov 2012Apr 2014Dec 2017Oct 2018

Another consideration is at the level of a unique overproduction of IL-6 in the present case of refractory PsoA, which could indicate a predominant autoinflammatory pattern over the autoimmune part of PsoA. In this regard, genomic DNA samples were isolated from the patient's peripheral blood, and whole exome sequencing and data analysis were performed on the proband as previously described \[[@CR16]\]. Publicly-available databases (ExAC, 1000 genomes, dbSNP, NHLBI GO Exome Sequencing Project and ClinSeq), as well as an in-house exome database, were used to filter for rare candidate variants. We did not identify any pathogenic mutations in known disease-causing genes. We analyzed the sequencing data for novel causes of immune dysregulation accounting for different modes of inheritance. Ideally, whole exome sequencing should be performed in trios to help with filtering a long list of candidate variants that are typically found when doing exome sequencing in singleton cases. Nonetheless, we did not identify any strong candidate variants to explain the phenotype. We also performed Sanger sequencing to analyze specific non-coding polymorphisms in the *IL6* promoter and 5′UTR that could potentially account for some of the patient's phenotype since the clinical spectrum of PsoA, more precisely the active peripheral arthritis, has been linked to IL6 (-174G/C) polymorphism \[[@CR17]\]. Coding regions as well as flanking 5′ untranslated regions of the *IL6* gene (RefSeq: NM_000600.5) were amplified by AmpliTaq Gold Fast PCR Master Mix (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA) and sequenced on SeqStudio Genetic Analyzer (Applied Biosystems Inc., Foster City, California, USA). We found that the patient had reference alleles at -597G, -572G, -473A8/T12 and -174G \[[@CR18]\]. We finally analyzed the data for common low-penetrance coding variants associated with psoriatic or rheumatoid arthritis. We found that the patient is a heterozygous carrier for the single nucleotide polymorphism (SNP) in *TRAF3IP2* rs33980500 (NM_001164281.2:c.28G\>A; p.Asp10Asn; NM_147200.2:c.55G\>A, NP_671733.2;p.Asp19Asn), which was identified by two genome-wide association studies (GWAS). The susceptibility allele rs33980500 has been shown to cause altered TRAF6 binding and thereby affect multiple immune pathways \[[@CR19], [@CR20]\]. Because TRAF3IP2 binding motifs have been associated with multiple TRAF proteins, the inhibition of the TRAF6 pathway could upregulate the TRAF2/5 pathway, leading to an enhanced immune response. Interestingly, studies showed that, in the TRAF6-independent pathway, TRAF2 and TRAF5 transduce the IL-17 signals to stabilize mRNA transcripts of chemokines and cytokines, such as CXCL1/GROα and IL-6 \[[@CR21], [@CR22]\]. Although these results did not identify a high penetrance genetic cause, they did identify a risk allele in *TRAF3IP2*, which in combination with additional environmental and genetic factors may help to explain this patient's phenotype and suggest a further link between the PsoA, IL-6 production and TRAF3IP2/TRAFs signalling (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3IL-6 production by blood leukocytes is altered in the RA-like PsoA patient in response to immune activators. In healthy individuals (top panel), the stimulation of peripheral blood mononuclear cells with immune activators leads to the activation of intracellular multiprotein oligomers (e.g. inflammasomes) and specific receptors that activate signalling pathways, including TRAF proteins, translocation of transcription factors and subsequent cytokine response. In the patient with aggressive RA-like PsoA (bottom panel), the activation of blood cells with anti-CD3 + anti-CD28, pro-inflammatory cytokines IL-1β, TNF and IFN-γ, muramyl dipeptide (MDP), lipopolysaccharide + adenosine triphosphate (LPS + ATP) and poly(deoxyadenylate--thymidylate) \[poly(dA:dT)\] led to a unique overproduction of IL-6 (red arrows). As the patient is a heterozygous carrier for a single nucleotide polymorphism p.Asp10Asn (p.D10N) in *TRAF3IP2*, this susceptibility allele causes altered TRAF6 binding (double red lines with an oblique stroke). The inhibition of the TRAF6 pathway could upregulate the TRAF2/5 pathway, leading to an enhanced immune response \[[@CR21], [@CR22]\] (dashed red arrow)

While we examined the secretome of blood cells, one limitation of this study is that many other cell types in autoimmune arthritis are known to secrete cytokines, such as synoviocytes, fibroblasts, chondrocytes, osteoblasts/osteoclasts and epithelial cells (the latter ones in psoriatic arthritis for example), and that these cells, through their cytokine secretion, could contribute to the local pathology \[[@CR23]--[@CR26]\]. The cytokine pattern could evidently be different from the ones produced by the blood cells. However, the use of these cells often requires invasive techniques to obtain them and their purification, for subsequent activation, is more labour-intensive than blood cells \[[@CR27]\]. It is also useful to stress that the presence of a SNP in *TRAF3IP2* rs33980500, as shown in this case report, should be present in all cell types using this signalling pathway \[[@CR28], [@CR29]\].

Conclusion {#Sec4}
==========

As a corollary and conclusion, an efficient way to effectively treat patients with complex autoimmune arthropathies, and to avoid irreversible disability, is to determine their blood leukocytes' secretome to identify abnormally secreted cytokines to personalize their biotherapy. Another concluding detail should also be noted as the finding of an abnormal patients' secretome can justify pursuing a causal investigation such as a genetic evaluation, as exemplified by this case report.
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